Evidence map›Paper›PMID 38860986›Full record

ArticleLangenbeck's archives of surgery2024

Prognosis and predictive factors of conversion surgery for initially unresectable advanced colorectal cancer.

Gaku Ohira, Satoshi Endo, Shunsuke Imanishi, Toru Tochigi, Tetsuro Maruyama, Koichi Hayano, Michihiro Maruyama, Hisahiro Matsubara

Abstract read
In one paragraph

Article in Langenbeck's archives of surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gaku OhiraDepartment of Frontier Surgery, Chiba university graduate school of medicine, 1-8-1 Inohana, Chuuou-ku, Chiba, 260-8670, Japan. Ohira@faculty.chiba-u.jp.
Satoshi EndoDepartment of Frontier Surgery, Chiba university graduate school of medicine, 1-8-1 Inohana, Chuuou-ku, Chiba, 260-8670, Japan.
Shunsuke ImanishiDepartment of Frontier Surgery, Chiba university graduate school of medicine, 1-8-1 Inohana, Chuuou-ku, Chiba, 260-8670, Japan.
Toru TochigiDepartment of Frontier Surgery, Chiba university graduate school of medicine, 1-8-1 Inohana, Chuuou-ku, Chiba, 260-8670, Japan.
Tetsuro MaruyamaDepartment of Frontier Surgery, Chiba university graduate school of medicine, 1-8-1 Inohana, Chuuou-ku, Chiba, 260-8670, Japan.
Koichi HayanoDepartment of Frontier Surgery, Chiba university graduate school of medicine, 1-8-1 Inohana, Chuuou-ku, Chiba, 260-8670, Japan.
Michihiro MaruyamaDepartment of Frontier Surgery, Chiba university graduate school of medicine, 1-8-1 Inohana, Chuuou-ku, Chiba, 260-8670, Japan.
Hisahiro MatsubaraDepartment of Frontier Surgery, Chiba university graduate school of medicine, 1-8-1 Inohana, Chuuou-ku, Chiba, 260-8670, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to report the outcomes of conversion surgery for initially unresectable advanced colorectal cancer and to identify factors that enable successful conversion surgery.

methodsWe compared the outcomes of patients with colorectal cancer with distant metastases, including extrahepatic metastases, who underwent upfront surgery, neoadjuvant chemotherapy, conversion surgery, and chemotherapy only at our department from 2007 to 2020. In addition, factors influencing the achievement of conversion surgery in patients who were initially unresectable were examined in univariate and multivariate analyses.

resultsOf 342 colorectal cancer patients with distant metastases treated during the study period, 239 were judged to be initially unresectable, and 17 (conversion rate: 7.1%) underwent conversion surgery. The prognosis for the conversion surgery group was better than that of the chemotherapy only group but worse than that of the upfront surgery group. In the conversion surgery group, the recurrence-free survival after resection was significantly shorter than that upfront surgery group and neoadjuvant chemotherapy group, and no patients have been cured. Among patients who were initially unresectable, left-sided primary cancer and normal CA19-9 level were identified as independent factors contributing to the achievement of conversion surgery in a multivariate analysis.

conclusionsAlthough relapse after conversion surgery is common, and no patients have been cured thus far, overall survival was better in comparison to patients who received chemotherapy only. Among unresectable cases, patients with left-sided primary cancer and normal CA19-9 levels are likely to be candidates for conversion surgery.

Indexed as

Colorectal NeoplasmsAdultAgedAged, 80 and overColectomyFemaleHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPrognosisRetrospective StudiesColorectal cancerConversion rateConversion surgeryExtrahepatic metastasesNeoadjuvant chemotherapy

Identifiers

PMID38860986
PMCPMC11166789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.